Pharma News

CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy designation from the FDA for its CTX130 for treatment of patients with either of two types of cutaneous T-cell lymphoma —...

Enalare Therapeutics has secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $50.3 million for its investigational respiratory stimulant ENA-001. ...

The FDA has granted a Priority Review to Pharming’s New Drug Application (NDA) for leniolisib to treat patients with activated phosphoinositide 3-kinase delta syndrome (APDS) who are 12 years an...

For the second time in 15 months, Japanese ophthalmology specialist Santen has earned an FDA approval for its eye drops.

Ayala Pharmaceuticals’ AL102 has gained Fast Track designation for the treatment of progressing desmoid tumors, which don’t metastasize but often aggressively infiltrate neurovascular structure...

NMD Pharma has received FDA’s Orphan Drug designation for its NMD670 candidate for treatment of myasthenia gravis.

Long ignored, dipole-dipole interactions give life its shape.

The European Medicines Agency (EMA) reported that Boehringer Ingelheim’s Actilyse (alteplase), Actilyse Cathlo (alteplase) and Metalyse (tenecteplase) are in short supply. ...

Pfizer and BioNTech have completed an Emergency Use Authorization (EUA) submission for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children between the ages of five and 11. ...

AstraZeneca and Merck have withdrawn Lynparza (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated ovarian cancer who have been treated wit...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) plus fulvestrant for National Health Service (NHS) use as a treatment for  ...

The FDA has granted Fast Track Designation for Atea Pharmaceuticals Inc's  AT-752 for treating dengue virus infection.